Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Rev. méd. Urug ; 38(2)jun. 2022.
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1389685

ABSTRACT

Resumen: Introducción: la hepatotoxicidad inducida por fármacos y otros agentes es una forma frecuente de injuria hepática, superando en algunos países a las hepatitis virales. La presentación es variable, desde una alteración aislada del funcional hepático hasta formas graves con fallo hepático agudo fulminante. Se presenta un caso de lesión hepática aguda luego de un ciclo corto con altas dosis de metilprednisolona intravenosa. Caso clínico: sexo femenino, 45 años. Antecedentes personales de esclerosis múltiple, con último empuje 40 días previo a la consulta, tratada con bolos de metilprednisolona intravenosa. Consulta por ictericia de una semana de evolución, dolor abdominal, vómitos, anorexia, astenia y adinamia en el último mes. De la paraclínica se destaca: hiperbilirrubinemia mixta, elevación de las transaminasas, tiempo de protrombina descendido. Se descarta etiología viral, autoinmune y metabólica. Se plantea hepatotoxicidad por metilprednisolona que se confirma con la evolución favorable, y normalización a los 3 meses del enzimograma hepático y tiempo de protrombina tras la suspensión del tratamiento con metilprdnisolona. Discusión: el primer paso para el diagnóstico de hepatotoxicidad es descartar otras causas de injuria hepática. En segundo lugar, se debe demostrar la relación temporal entre la exposición al fármaco y el daño hepático. Por último, la suspensión del medicamento suele acompañarse de mejoría del cuadro clínico y analítico. Para diagnosticar esta entidad es necesario tener un alto índice de sospecha. El tratamiento con dosis altas de metilprednisolona puede inducir hepatitis severa que recurre con la re-exposición a la droga. Los pacientes con enfermedades autoinmunes tienen mayor riesgo de desarrollar hepatotoxicidad, lo que plantea un desafío terapéutico.


Summary: Introduction: drug induced hepatotoxicity and toxicity induced by other agents is a frequent form of liver injury, accounting for larger number of cases than viral hepatitis in some countries. Presentation may be variable, from an isolated alteration in the liver function test to severe forms of acute fulminant liver failure. The study presents a case of severe liver injury following a short cycle with high doses of intravenous methylprednisolone. Clinical case: 45 year-old female patient. Personal history of multiple sclerosis, with relapse 40 days prior to the consultation, treated with intravenous methylprednisolone. The patient consulted for jaundice with one week of evolution, abdominal pain, vomiting, anorexia, asthenia, and adynamia in the last month. Paraclinical tests find mixed hyperbilirubinemia, increased transaminases and decreased prothrombin time (PT). Viral, autoimmune and metabolic etiology are ruled out and a hypothesis is made for methylprednisolone-induced hepatotoxicity. The latter is confirmed and evolution is favorable, liver enzymogram being normal after three months, the same as the prothrombin time upon the interruption of methylprednisolone therapy. Discussion: the first step to diagnose hepatotoxicity is excluding other causes of liver injury. Next, the temporal relationship between drug exposure and liver injury needs to be demonstrated. Last, withdrawing the drug is usually accompanied by clinical and tests improvement. A high degree of suspicion is necessary to diagnose this condition. Therapies with high doses of methylprednisolone may cause severe hepatitis, and it is recurrent upon re-exposure to the drug. Patients with autoimmune diseases have greater risks of developing hepatotoxicity, what results in a therapeutic challenge.


Resumo: Introdução: a hepatotoxicidade induzida por drogas e outros agentes é uma forma frequente de lesão hepática, superando as hepatites virais em alguns países. A apresentação é variável, desde uma alteração isolada da função hepática até formas graves com insuficiência hepática aguda fulminante. Um caso de lesão hepática aguda após um curto curso de metilprednisolona intravenosa em altas doses é apresentado. Caso clínico: sexo feminino, 45 anos. Antecedentes pessoais de esclerose múltipla, com último impulso 40 dias antes da consulta, tratados com bolus de metilprednisolona endovenosa. Consulta por icterícia de uma semana de evolução, dor abdominal, vômitos, anorexia, astenia e adinamia no último mês. Dos exames paraclínicos, destacam-se: hiperbilirrubinemia mista, transaminases elevadas, tempo de protrombina diminuído. A etiologia viral, autoimune e metabólica é descartada. Foi sugerida hepatotoxicidade por metilprednisolona, confirmada pela evolução favorável, e normalização aos 3 meses da enzima hepática e do tempo de protrombina após a interrupção do tratamento com metilprednisolona. Discussão: o primeiro passo no diagnóstico de hepatotoxicidade é descartar outras causas de lesão hepática. Em segundo lugar, a relação temporal entre a exposição à droga e o dano hepático deve ser demonstrada. Por fim, a suspensão do medicamento costuma ser acompanhada de melhora do quadro clínico e analítico. Para diagnosticar esta entidade é necessário ter um alto índice de suspeição. O tratamento com altas doses de metilprednisolona pode induzir hepatite grave que se repete na reexposição ao medicamento. Pacientes com doenças autoimunes apresentam risco aumentado de desenvolver hepatotoxicidade, o que representa um desafio terapêutico.


Subject(s)
Methylprednisolone/adverse effects , Chemical and Drug Induced Liver Injury
2.
Rev. Assoc. Med. Bras. (1992) ; 66(10): 1414-1416, Oct. 2020. graf
Article in English | SES-SP, LILACS | ID: biblio-1136140

ABSTRACT

SUMMARY The relationship between acute pancreatitis and the administration of glucocorticoids is unclear because most reported cases have been diagnosed with systemic vascular diseases, such as systemic lupus erythematosus, which may be responsible for pancreatitis. A 22-year-old woman with eye involvement of a newly diagnosed systemic lupus erythematosus was admitted to our hospital. Pulse intravenous methylprednisolone therapy was given at 1mg/kg day for 3 days, and oral prednisolone at 40 mg/day thereafter. During pulse steroid therapy, she had abdominal pain, back pain, distention, nausea, and vomiting. Her physical examination was compatible with acute abdomen and peritonitis. Abdomen Computerized Tomography scan revealed diffuse liquid perihepatic and perisplenic area with heterogeneity around the mesentery. Due to the symptoms of acute abdomen, explorative laparotomy was performed. There was diffuse free fluid in the abdomen and edematous changes were observed around the pancreas. Amylase and lipase from intraabdominal fluid were studied and found to be high. The postoperative prednol dose was reduced carefully. On the sixth postoperative day, the drain was removed, and the patient was discharged without any problem. Physicians should keep in mind that acute pancreatitis may also be a cause of differential diagnosis of newly developed abdominal pain in patients receiving pulse steroid therapy with a normal level of serum amylase and lipase.


RESUMO A relação entre pancreatite aguda e a administração de glicocorticoides é incerta pois a maioria dos casos relatados foram diagnosticados com doenças vasculares sistêmicas, como lúpus eritematoso sistêmico, que pode causar pancreatite. Uma paciente de 22 anos com envolvimento ocular e lúpus eritematoso sistêmico recém-diagnosticado foi admitida em nosso hospital. Pulsoterapia intravenosa com metilprednisolona 1mg/kg foi administrada por 3 dias. Depois disso, a paciente foi tratada com prednisolona oral 40 mg/dia. Durante a pulsoterapia com corticoides, a paciente apresentava dor abdominal, dor nas costas, distensão, náusea e vômitos. O exame físico era compatível com quadro de abdome agudo e peritonite. Tomografia computadorizada do abdome revelou líquido difuso na região perihepática e periesplênica, com heterogeneidade ao redor do mesentério. Devido aos sintomas de abdome agudo, foi realizada laparotomia exploradora. Havia líquido livre difuso no abdome e alterações edematosas foram observadas em torno do pâncreas. A amilase e lipase do líquido intra-abdominal foram analisadas e consideradas elevadas. A dose pós-operatória de prednol foi reduzida com cuidado. No sexto dia de pós-operatório, o dreno foi retirado, e a paciente recebeu alta sem qualquer problema. Médicos devem lembrar que a pancreatite aguda também pode ser uma causa de diagnóstico diferencial para dor abdominal recém-desenvolvida em pacientes recebendo pulsoterapia com corticoides e com níveis normais de amilase e lipase séricas.


Subject(s)
Humans , Female , Young Adult , Pancreatitis/chemically induced , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/chemically induced , Methylprednisolone/adverse effects , Acute Disease , Adrenal Cortex Hormones
3.
Adv Rheumatol ; 59: 6, 2019. tab, graf
Article in English | LILACS | ID: biblio-1088584

ABSTRACT

Abstract Background: Recommendations of the Myopathy Committee of the Brazilian Society of Rheumatology for the management and therapy of systemic autoimmune myopathies (SAM). Main body: The review of the literature was done in the search for the Medline (PubMed), Embase and Cochrane databases including studies published until June 2018. The Prisma was used for the systematic review and the articles were evaluated according to the levels of Oxford evidence. Ten recommendations were developed addressing the management and therapy of systemic autoimmune myopathies. Conclusions: Robust data to guide the therapeutic process are scarce. Although not proven effective in controlled clinical trials, glucocorticoid represents first-line drugs in the treatment of SAM. Intravenous immunoglobulin is considered in induction for refractory cases of SAM or when immunosuppressive drugs are contra-indicated. Consideration should be given to the early introduction of immunosuppressive drugs. There is no specific period determined for the suspension of glucocorticoid and immunosuppressive drugs when individually evaluating patients with SAM. A key component for treatment in an early rehabilitation program is the inclusion of strengthbuilding and aerobic exercises, in addition to a rigorous evaluation of these activities for remission of disease and the education of the patient and his/her caregivers.


Subject(s)
Adult , Humans , Autoimmune Diseases/drug therapy , Glucocorticoids/therapeutic use , Immunosuppressive Agents/therapeutic use , Muscular Diseases/drug therapy , Rheumatology , Societies, Medical , Autoimmune Diseases/rehabilitation , Brazil , Methylprednisolone/administration & dosage , Methylprednisolone/adverse effects , Prednisone/administration & dosage , Prednisone/adverse effects , Biomarkers/blood , Exercise , Randomized Controlled Trials as Topic , Patient Education as Topic , Immunoglobulins, Intravenous/therapeutic use , Polymyositis/therapy , Dermatomyositis/therapy , Exercise Therapy , Rituximab/therapeutic use , Glucocorticoids/adverse effects , Immunosuppressive Agents/adverse effects , Muscular Diseases/rehabilitation
4.
Arq. neuropsiquiatr ; 71(9B): 659-660, set. 2013. tab
Article in English | LILACS | ID: lil-688536

ABSTRACT

Iatrogenic meningitis can be caused by a number of mechanisms. The recent case reports of fungal meningitis after application of epidural methylprednisolone caused warning in the medical community. Cases were caused by contaminated lots of methylprednisolone from a single compounding pharmacy. Several medications can cause meninigitis by probable hypersensitivity mechanism. Neurologists should be alert to the recent description of the use of lamotrigine and development of aseptic meningitis.


As meningites iatrogênicas podem ser provocadas por uma série de mecanismos. Os recentes relatos de casos de meningite por fungos após a aplicação de injeção epidural de metilprednisolona causou alerta na comunidade médica. Os casos foram causados por lotes contaminados de metilprednisolona produzidos por uma única farmácia de produção. Diversos medicamentos podem causar meningite por provável mecanismo de hipersensibilidade. Neurologistas devem ficar alerta para a recente descrição do uso de lamotrigina e o desenvolvimento de meningite asséptica.


Subject(s)
Humans , Drug Contamination , Iatrogenic Disease , Meningitis, Aseptic/chemically induced , Meningitis, Fungal/microbiology , Methylprednisolone/adverse effects , Neuroprotective Agents/adverse effects
6.
Clinics ; 68(1): 85-92, Jan. 2013. graf, tab
Article in English | LILACS | ID: lil-665923

ABSTRACT

OBJECTIVES: Administering steroids before cardiopulmonary bypass in pediatric heart surgery modulates systemic inflammatory response syndrome and improves postoperative recovery. However, the use of steroids aggravates hyperglycemia, which is associated with a poor prognosis. Adult patients with systemic inflammatory response syndrome usually evolve with hyperglycemia and high insulin levels, whereas >90% of pediatric patients exhibit hyperglycemia and low insulin levels. This study aims to determine: A) the metabolic and inflammatory factors that are associated with hyperglycemia and low insulin levels in children who underwent cardiac surgery with cardiopulmonary bypass and who received a single high dose of methylprednisolone and B) the best predictors of insulin variation using a mathematical model. METHODS: This preliminary study recruited 20 children who underwent heart surgery with cardiopulmonary bypass and received methylprednisolone (30 mg/kg) immediately after anesthesia. Among the 20 patients initially recruited, one was excluded because of the absence of hyperglycemia and lower insulin levels after surgery. However, these abnormalities were confirmed in the remaining 19 children. The C-peptide, CRP, IL-6, and adrenomedullin levels were measured before surgery, immediately after cardiopulmonary bypass, and on the first, second, and third days after cardiac surgery. RESULTS: IL-6, CRP, and adrenomedullin increments were observed, whereas the C-peptide levels remained within reference intervals. CONCLUSION: The multiple regression model demonstrated that in addition to age and glycemia (two well-known factors that are directly involved in glucose metabolism), adrenomedullin and IL-6 levels were independent factors associated with lower insulin concentrations. These four parameters were responsible for 64.7% of the observed insulin variances. In addition, the fact that C-peptide levels did not fall together with insulin could have grounded the medical decision not to administer insulin to patients.


Subject(s)
Child, Preschool , Female , Humans , Infant , Male , Anti-Inflammatory Agents/adverse effects , Cardiac Surgical Procedures/methods , Cardiopulmonary Bypass/methods , Hyperglycemia/chemically induced , Insulin/blood , Methylprednisolone/adverse effects , Age Factors , Adrenomedullin/blood , Anti-Inflammatory Agents/administration & dosage , Blood Glucose/analysis , Blood Glucose/drug effects , C-Peptide/blood , C-Reactive Protein/analysis , Insulin/deficiency , /blood , Models, Biological , Methylprednisolone/administration & dosage , Postoperative Period , Reference Values , Regression Analysis
7.
Arch. argent. pediatr ; 110(6): e118-e122, dic. 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-662135

ABSTRACT

Una adolescente con leucemia linfoblástica aguda desarrolló un síndrome de lisis tumoral precoz y grave con lesión renal aguda luego de una dosis única y baja de esteroides. La disfunción renal se atribuyó primariamente a una nefropatía por fosfato con nefrocalcinosis debido a elevaciones extremas de este componente en sangre. La alcalinización urinaria probablemente contribuyó a su patogenia. Se utilizó diálisis peritoneal con resolución de la nefrocalcinosis y normalización de la depuración de creatinina.


An adolescent with acute lymphoblastic leukemia developed an early and severe tumor lysis syndrome with acute kidney injury after a low and single dose of steroids. Renal dysfunction was attributed primarily to phosphate nephropathy with nephrocalcinosis due to extreme elevations of phosphate in blood. Urinary alkalinization probably contributed to this development. We used peritoneal dialysis with resolution of nephrocalcinosis and normalization of creatinine clearance.


Subject(s)
Adolescent , Child , Female , Humans , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Peritoneal Dialysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Tumor Lysis Syndrome/complications , Acute Kidney Injury/urine , Alkalies/urine , Glucocorticoids/adverse effects , Methylprednisolone/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Tumor Lysis Syndrome/etiology
8.
Rev. Assoc. Med. Bras. (1992) ; 58(1): 125-128, jan.-fev. 2012. tab
Article in English | LILACS | ID: lil-617119

ABSTRACT

OBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66 percent, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68 percent, 94 percent and 98 percent, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.


OBJETIVO: Pulsos de metilprednisolona são usados em diversas doenças, tanto para tratamento agudo quanto crônico. Embora bem tolerados, eles aumentam os níveis de glicose em ambos os pacientes, não diabéticos e diabéticos. Eles também podem ser considerados um risco significativo para alterações metabólicas agudas. O propósito deste estudo é determinar as alterações metabólicas nos níveis de glicose no sangue de pacientes não diabéticos que recebem pulsos de metilprednisolona e identificar a presença de fatores preditivos para seu desenvolvimento. MÉTODOS: Estudo observacional prospectivo em 50 pacientes não diabéticos que recebem pulsoterapia com 1 g de metilprednisolona intravenosa por três dias consecutivos como tratamento para diversas doenças autoimunes. Variáveis demográficas, antropométricas e metabólicas foram analisadas, e glicose, insulina e níveis de peptídeo C foram identificados após cada pulso de esteroide. Diferentes variáveis e a magnitude da hiperglicemia foram analisadas utilizando a correlação de Pearson. RESULTADOS: 50 pacientes foram incluídos, predominantemente mulheres (66 por cento, n = 33). A idade média foi de 41 ± 14 anos com um IMC de 26 ± 3 kg/m². A glicose de base foi de 83 ± 10 mg/dL. Após cada pulso de esteroide, a glicose aumentou para 140 ± 28, 160 ± 38 e 183 ± 44, respectivamente (p < 0,001). Peptídeo C e concentrações de insulina aumentaram significativamente (p < 0,001). A prevalência de hiperglicemia em jejum após cada pulso foi de 68 por cento, 94 por cento e 98 por cento, respectivamente. Não encontramos nenhuma correlação entre a magnitude da hiperglicemia e as variáveis estudadas. CONCLUSÃO: Os pulsos de metilprednisolona produziram aumentos significativos na glicemia de jejum na maioria dos pacientes sem diabetes. Mais estudos são necessários para definir o seu papel nas consequências em longo prazo.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Blood Glucose/drug effects , Glucocorticoids/adverse effects , Hyperglycemia/chemically induced , Methylprednisolone/adverse effects , Blood Glucose/metabolism , Hyperglycemia/metabolism , Mexico , Prospective Studies , Pulse Therapy, Drug , Risk Factors
9.
IJRM-Iranian Journal of Reproductive Medicine. 2012; 10 (4): 363-372
in English | IMEMR | ID: emr-132389

ABSTRACT

Osteoporosis is a chronic disease characterized by a decrease in bone mineral density [BMD] and corruption of the microarchitectural structure of bone tissue. It was investigated whether methylprednisolone had a favorable effect on osteoporotic bone tissue in Oophorectomy induced osteoporotic rats whose endogenous adrenaline levels are suppressed with metyrosine. Bone Mineral Density, number of osteoblast-osteoclast, bone osteocalcin levels and alkaline phosphatase [ALP] measurements were performed. Obtained results were compared with that of alendronate. Oophorectomy induced osteoporosis was exacerbated by methylprednisolone. Alentronate prevented ovariectomised induced osteoporosis, but it couldn't prevent methylprednisolone +ovariectomised induced osteoporosis in rats. Combined treatment with methylprednisolon and metyrosine was the best treatment for preventing osteoporosis but metyrosine alone couldn't prevent osteoporosis in ovariectomised rats


Subject(s)
Female , Animals, Laboratory , Methyltyrosines , Rats , Osteoclasts/drug effects , Prednisolone , Prednisolone/adverse effects , Drug Combinations , Ovariectomy/adverse effects , Osteoblasts/drug effects , Bone Density/drug effects , Methylprednisolone/adverse effects , Methylprednisolone , Osteocalcin/drug effects , Alkaline Phosphatase , Alendronate , Treatment Outcome
10.
Rev. dor ; 11(1)jan.-mar. 2010.
Article in Portuguese | LILACS | ID: lil-562437

ABSTRACT

JUSTIFICATIVA E OBJETIVOS: A infiltração anestésica do músculo psoas para tratamento da síndrome dolorosa miofascial apresenta reconhecida eficácia, tendo como complicações estabelecidas a infecção local e o hematoma. O objetivo do presente estudo foi relatar um caso de síndrome dolorosa miofascial do músculo psoas com complicação decorrente do tratamento intervencionista.RELATO DO CASO: Paciente do sexo feminino, 49 anos, com queixa de dor lombar e abdominal há cinco anos, com piora há dois anos. Na consulta relatou dor lombar, com irradiação para a região inguinal esquerda, contínua, com intensidade 8 pela escala analógica visual (EAV), apesar do uso de fórmula contendo fluoxetina, meloxicam e amitriptilina. A hipótese diagnóstica foi de síndrome dolorosa miofascial do psoas, sendo realizada infiltração anestésica do músculo, com alívio imediato e completo da dor. Dezoito dias após o procedimento a paciente apresentou dor de intensidade 6 e com história clínica compatível com hematoma subagudo. Trinta e cinco dias após o primeiro exame, a ressonância nuclear magnética (RNM) mostrou regressão total da coleção intramuscular, com persistência apenas de tênue área de edema e realce mio-fibrilar. Realizou-se infiltração muscular com toxina botulínica medicamentosa com duloxetina (60 mg/dia), sendo obtida a remissão total do quadro doloroso. CONCLUSÃO: O caso mostrou a eficácia da infiltração do músculo psoas com anestésico local e corticoide como medida terapêutica indicada para relaxamento muscular imediato, com desativação dos pontos-gatilho e consequente alívio da dor, acelerando assim o processo de recuperação e mostrou que o hematoma é uma complicação que pode ser resolvida com tratamento clínico.


BACKGROUND AND OBJECTIVES: Anesthetic infiltration of the psoas muscle to treat painful myofascial syndrome is recognized as effective and has as established complications local infection and hematoma. This study aimed at reporting a case of psoas muscle painful myofascial syndrome with a complication caused by the interventional treatment.CASE REPORT: Female patient, 49 years old, with lumbar and abdominal pain complaint for five years which has worsened in the last two years. Patient reported lumbar pain, with irradiation to the left inguinal region, continuous, with intensity 8 according to visual analog scale (VAS), in spite of using a formula with fluoxetine, meloxicam and amitriptyline. Diagnostic hypothesis was painful psoas myofascial syndrome. The muscle was infiltrated with anesthetics with immediate and complete pain relief. Eighteen days after the procedure, patient presented pain of intensity 6 and with clinical history compatible with sub-acute hematoma. Thirty-five days after the first exam, MRI has shown total regression of the intramuscular collection with persistence of just a subtle area of edema and myo-fibrillary enhancement. Muscle was infiltrated with botulinic toxin drug with duloxetine (60 mg/day), with total remission of pain. CONCLUSION: This case has shown the efficacy of infiltrating the psoas muscle with local anesthetics and steroid as therapeutic measure indicated for immediate muscle relaxation, with deactivation of trigger-points and consequent pain relief, thus accelerating the recovery process, and has shown that hematoma is a complication which may be solved with clinical treatment


Subject(s)
Humans , Female , Middle Aged , Anti-Inflammatory Agents , Hematoma/chemically induced , Injections, Intramuscular , Methylprednisolone/adverse effects , Myofascial Pain Syndromes/drug therapy , Trigger Points , Psoas Abscess/chemically induced , Methylprednisolone/analogs & derivatives , Psoas Muscles
11.
Rev. Assoc. Med. Bras. (1992) ; 55(6): 729-737, 2009. tab
Article in Portuguese | LILACS | ID: lil-538505

ABSTRACT

A corticoterapia tem sido testada como protetor neuronal no trauma. Os estudos multicêntricos avaliando a metilprednisolona (MP) na recuperação neurológica após trauma revelaram-se promissores (NASCIS). Porém, várias, críticas às suas metodologias foram publicadas. OBJETIVO: Revisar a literatura relacionada ao uso da metilprednisolona comparada com placebo. MÉTODOS: A análise feita somou a média da melhora obtida nos grupos de pacientes que usaram MP e placebo (PL) à média dos escores dos grupos na linha de base, antes de tratamento, obtendo-se o resultado neurológico final de ambos os grupos. RESULTADOS: O escore motor do grupo MP foi apenas 2,5 pontos maior que o PL em um ano de seguimento. O escore motor em indivíduos intactos é de 70 pontos. A melhora nos escores sensitivos foi igualmente discreta (1,1 e 1,7 pontos para sensibilidade a picadas e tato respectivamente). A taxa de complicações observada em grupo de pacientes em torno de 60 anos foi alta com o uso de MP. CONCLUSÃO: As diferenças na magnitude do benefício clínico obtido (não confirmado por outros estudos) com o uso da MP e com o PL não são significativas em confronto com o potencial de complicações do uso da medicação.


Steroid therapy has been tested as a protector in spinal cord injury. Multicenter studies evaluating the methylprednisolone (MP) in post traumatic neurological recovery have shown promising results according to NASCIS. A large number of critical studies related to the NASCIS results have been published. OBJECTIVE: To review literature related to use of methylprednisolone compared with placebo. METHODS: This analysis added the average improvement achieved in groups of patients who used MP and placebo (PL) to the average scores of groups at baseline, before treatment, resulting in the final neurological outcome for both groups. RESULTS: The motor score of the MP group was only 2.5 points higher than the PL in a one year follow-up. In neurologically intact patients, the total score is 70 points. Improvement in sensitive scores was also discrete (1.1 and 1.7 points for the pinprick and light touch respectively). A high rate of complications was observed in a group of patients about 60 years old who used MP. CONCLUSION: Differences in the clinical magnitude of benefit obtained (not confirmed by other studies) with the use of MP or PL are not significant, in comparison with the potential for complications when using methylprednisolone.


Subject(s)
Humans , Methylprednisolone/therapeutic use , Neuroprotective Agents/therapeutic use , Spinal Cord Injuries/drug therapy , Methylprednisolone/adverse effects , Neuroprotective Agents/adverse effects , Placebos/therapeutic use , Randomized Controlled Trials as Topic
14.
Article in English | IMSEAR | ID: sea-64231

ABSTRACT

We report clinically significant, recurrent acute hepatitis in a 48-year-old woman receiving pulsed treatment with methylprednisolone for multiple sclerosis. No other cause was found for the episodes and the temporal and histological correlations were consistent with immune-allergic type drug-induced hepatitis.


Subject(s)
Acute Disease , Drug Hypersensitivity/diagnosis , Female , Glucocorticoids/adverse effects , Chemical and Drug Induced Liver Injury/diagnosis , Humans , Liver/pathology , Methylprednisolone/adverse effects , Middle Aged , Multiple Sclerosis/drug therapy , Recurrence
15.
Med. intensiva ; 17(1): 9-14, 2000. ilus, tab
Article in Spanish | LILACS | ID: lil-273716

ABSTRACT

Los estudios randomizados representan una de las más elegantes soluciones para evitar las desinteligencias en la interpretación del efecto terapeútico en presencia de problemas complejos. Sin embargo los estudios randomizados son muy costosos, difíciles de implementar y algunas veces imposibles de realizar por enfrentar problemas bioéticos insolubles. Debido a ésto es quizás que solamente el 20 por ciento de las guías clínicas se basan en sus resultados. Se discuten además estudios randomizados en SDRA


Subject(s)
Humans , Evidence-Based Medicine/statistics & numerical data , Randomized Controlled Trials as Topic/statistics & numerical data , Respiratory Distress Syndrome/classification , Evidence-Based Medicine/standards , Methylprednisolone/adverse effects , Multicenter Studies as Topic/trends , Randomized Controlled Trials as Topic/standards , Respiratory Distress Syndrome/drug therapy
16.
Rev. paul. pediatr ; 15(4): 177-80, dez. 1997.
Article in Portuguese | LILACS | ID: lil-227989

ABSTRACT

Foram tratadas 11 crianças com Síndrome Nefrótica, 10 corticoresistentes e 1 corticodependente, com pulsos de metilprednisolona por via endovenosa. Todas as crianças receberam prednisona por via oral diariamente em dose

Subject(s)
Humans , Child, Preschool , Child , Methylprednisolone/therapeutic use , Nephrotic Syndrome/drug therapy , Methylprednisolone/adverse effects
17.
Arch. argent. dermatol ; 46(6): 257-66, nov.-dic. 1996. ilus
Article in Spanish | LILACS | ID: lil-196990

ABSTRACT

Observación prospectiva de lesiones dermatológicas en pacientes con trasplantes renales. Tiempo de inmunosupresión: entre 0 a 22 años (X:106,1ñ81,7 meses). Período de observación: 3 años (5/1991 - 7/1994). Pacientes de sexo masculino: 70 por ciento. Edad media de población estudiada: 39,9 años (X: 39,9ñ13,2 años). El 71 por ciento de los pacientes eran receptores de donante vivo, sólo 9 de ellos no relacionados. 71 recibían tripleterapia, 27 terapia clásica y 2 dobleterapia. El 99 por ciento de los pacientes presentaron dermopatías relacionadas con la inmunosupresión, con predominio de lesiones secundarias a drogas (82 por ciento) e infecciones virales (51 por ciento). Las lesiones vinculables al virus del papiloma humano (HPV) se detectaron en el 44 por ciento de la población y en un 100 por ciento de aquellos pacientes con más de 8 años de inmunosupresión. El 8 por ciento de los pacientes desarrollaron cánceres de piel, con una relación entre epitelioma basocelular y carcinoma epidermoide de 1:1. Se comprueba que las lesiones por infecciones micóticas, bacterianas y secundarias a drogas predominan en los primeros 5 años de trasplante, mientras que las lesiones por infecciones virales, pretumorales y tumorales aparecieron luego de 5 años de inmunosupresión. Ello demuestra la influencia del tiempo de inmunosupresión como factor favorecedor de estas tres últimas patologías. Se efectúa un análisis de los factores de inmunosupresión en función del tiempo, considerando las drogas, rayos ultravioletas, características genéticas y edad cronológica de los pacientes. Estos factores, asociados a una posible acción oncogénica de algunos HPV, serían los desencadenantes del cáncer de piel, el tumor maligno de mayor incidencia en los pacientes con trasplante renal


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Immunosuppressive Agents/adverse effects , Immunosuppression Therapy/adverse effects , Kidney Transplantation/adverse effects , Skin Manifestations , Acne Vulgaris/etiology , Azathioprine/administration & dosage , Azathioprine/adverse effects , Azathioprine/therapeutic use , Carcinoma, Squamous Cell/etiology , Carcinoma, Basal Cell/complications , Cyclosporine/administration & dosage , Cyclosporine/adverse effects , Cyclosporine/therapeutic use , Hypertrichosis/etiology , Immunosuppressive Agents/pharmacology , Immunosuppression Therapy/methods , Methylprednisolone/administration & dosage , Methylprednisolone/adverse effects , Methylprednisolone/therapeutic use , Papilloma/complications , Prospective Studies , Skin Neoplasms/etiology , Tinea Versicolor/etiology
19.
Med. intensiva ; 12(1): 23-30, abr. 1995. ilus
Article in Spanish | LILACS | ID: lil-168473

ABSTRACT

Estudio prospectivo, randomizado. Se ingresaron 64 pacientes de ambos sexos, edad promedio 48 años. Criterios de inclusión: 5 evidencias clínicas de entre las siguientes: fiebre o hipotermia; oliguria; taquicardia; hipotensión; taquipnea; cianosis u otro signo de hipoxemia; modificaciones de la conciencia (obnubilo, confusión, signos meníngeos, exitación psicomotriz, delirio); trastornos digestivos (hemorragias, vómitos, diarreas); vasoplejía o vasoconstricción. Los criterios de exclusión fueron: taras orgánicas previas (insuficiencia adrenal o renal); diabetes; úlcera péptica; tuberculosis; micosis sistémica; sensibilidad corticoidea; enfermedades de inmunodeficiencia; edad ( de 70); embarazo; lactancia. El lote total de enfermos fue dividido en 2 grupos iguales: PC y MPS; este último con aporte precoz a la dosis de 30 mg/kg/vez, repetida a las 6 y 18 horas de la inicial. Se monitorizaron en todos los casos parámetros clínicos y de laboratorio de uso corriente en terapia intensiva; las evoluciones estuvieron (en cuanto al momento de efectuadas) relacionadas con la primera megadosis de MPS: inmediatamente antes, a las 24, 48, 72 y 120 horas. Los resultados obtenidos para la sobrevida fueron similares en los enfermos de ambos grupos; en la regresión del síndrome de shock observamos una ligera disminución en el tiempo transcurrido (alrededor de un 10 por ciento) para la remisión sintomatológica en aquellos pacientes tratados con megadosis MPS, en relación a los del grupo PC. Concluímos que esta experiencia es indicativa de prescindencia del uso de MPS en macrodosis en la terapéutica del shock séptico; además, la relación costo-beneficio no es proporcional


Subject(s)
Humans , Female , Adult , Middle Aged , Shock, Septic/drug therapy , Methylprednisolone/administration & dosage , Case-Control Studies , Shock, Septic/mortality , Methylprednisolone/adverse effects , Methylprednisolone/therapeutic use , Outcome Assessment, Health Care/statistics & numerical data , Prospective Studies , Treatment Outcome
20.
Rev. bras. reumatol ; 34(3): 140-6, maio-jun. 1994.
Article in Portuguese | LILACS | ID: lil-169261

ABSTRACT

Trata-se de um trabalho em que sao apresentadas as diversas modalidade de pulsoterapia, com classificaçao original do autor e consideraçoes específicas das distintas variedades desse método terapêutico. Destaca-se a pulsoterapia com metilprednisolona, com ciclofosfamida, com metotrexato e a associada, em que se utilizam simultaneamente duas drogas. Além das principais indicaçoes e contra-indicaçoes, com critérios de inclusao e de exclusao, referem-se as respectivas técnicas de administraçao e posologia, bem como os mecanismos de açao, efeitos adversos e resultados


Subject(s)
Humans , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cyclophosphamide , Cyclophosphamide/therapeutic use , Methotrexate/administration & dosage , Methotrexate/adverse effects , Methotrexate , Methotrexate/therapeutic use , Methylprednisolone/administration & dosage , Methylprednisolone/adverse effects , Methylprednisolone , Methylprednisolone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL